Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPLIM: Effect of dapagliflozin on energy metabolism in type 2 diabetes
jRCTs051180091Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Hepatocellular adenosine triphosphate (ATP) concentrations. Started Mar 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051180091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180091.